Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pancrelipase Clear all
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT00788593
View directory record Official record
Conditions
Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions
Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 23, 2026, 8:53 PM EDT
Not listed Not applicable Interventional

Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer

NCT01771146
View directory record Official record
Conditions
Pancreas Cancer, Localized Pancreas Cancer, Non-metastatic Pancreas Cancer
Interventions
FOLFIRINOX Regimen
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 23, 2026, 8:53 PM EDT
Terminated No phase listed Observational

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

NCT01652157
View directory record Official record
Conditions
Fibrosing Colonopathy
Interventions
ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy
Biological · Other
Lead sponsor
AbbVie
Industry
Eligibility
0 Months to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
123
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Not applicable Interventional Results available

Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients

NCT00510744
View directory record Official record
Conditions
Obesity
Interventions
pancreatic enzyme supplement
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 23, 2026, 8:53 PM EDT
Withdrawn Not applicable Interventional

Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients

NCT00663975
View directory record Official record
Conditions
Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
DCI 1020
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
Up to 2 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2010 · Synced Sep 23, 2026, 8:53 PM EDT
Withdrawn Phase 2 Interventional

Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis

NCT02706236
View directory record Official record
Conditions
Pancreatitis
Interventions
Pancrelipase, placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

NCT00408317
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Ultrase® MT20, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 4 Interventional Results available

PR-018: An Open-Label, Safety Extension of Study PR-011

NCT01131507
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 12 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Jacksonville, Florida • Las Vegas, Nevada • Akron, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 23, 2026, 8:53 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

NCT03469258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pancrelipase
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 23, 2026, 8:53 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Assess the Safety and Efficacy of ANG003

NCT07450547
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
ANG003 Dose A, ANG003 Dose B, Creon
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 4 Interventional Results available

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT03924947
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pancrelipase
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Ventura, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Fat Malabsorption in Chronic Pancreatitis

NCT02849704
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Creon36™
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
30 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 23, 2026, 8:53 PM EDT
Terminated Phase 1 Interventional Results available

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

NCT01142128
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

NCT00981214
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 7 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

NCT00775528
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase Delayed Release
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
1 Month to 6 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Boise, Idaho • Louisville, Kentucky • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2010 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 4 Interventional

Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

NCT01641341
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Bifidobacterium infantis, Pancrelipase, Nitazoxanide, Placebo
Drug
Lead sponsor
American Academy of Family Physicians
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Lomita, California • Leawood, Kansas • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 3 Interventional

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

NCT00432861
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
PANCRECARB® (pancrelipase), Placebo
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

NCT00880100
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT12
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Years to 6 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
15
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Grand Rapids, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 23, 2026, 8:53 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

NCT05069597
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Pancreatitis
Interventions
CREON
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 23, 2026, 8:53 PM EDT